Company Overview and News

14
Bear of the Day: Alaska Air Group (ALK)

2018-09-11 zacks
Shares of Alaska Air Group (ALK - Free Report) , which owns Alaska Airlines and Horizon Air, have slipped roughly 8% since the start of the year due to rising fuel costs. ALK stock has jumped over the last three months, but the firm’s outlook doesn’t seem very promising.
SWRAY SWRBY SKYW ALK AFLYY HOME VA AFRAF GM SWRBF SWRAF

30
Bear of the Day: American Airlines (AAL)

2018-08-29 zacks - 2
American Airlines Group Inc. (AAL - Free Report) has seen its stock price plummet 24% over last the six months, and things don’t look like they are going to get much better for the airline powerhouse.
SWRAY SWRBY AAL SKYW AFLYY NWL AFRAF URBN 500570 SWRBF SWRAF TATAMOTORS TTM

2
Lackluster Assets And No Real Dynamism Continue To Weigh On CK Hutchison Holdings

2018-06-21 seekingalpha - 1
CK Hutchison's parts and pieces continue to generate so-so results, with not much growth in the high-margin telco business and weak same-store sales growth in retail.
SWRAY HSE CTPCF SWRBY CKHUY HUSKF SWRBF SWRAF

3
Hong Kong shares gain on investors’ optimism over Trump Kim summit

2018-06-11 scmp
Hong Kong stocks closed moderately higher on Monday ahead of a historic US-North Korea summit that investors hope might lead to peace on the Korean peninsula.
SWRAY GELYF SJMHY MDEVF 0175 1128 PXGYF 1928 SWRBF ALBHF 2282 SWRBY SCHYF WYNMF MCHVF GELYY 0200 0880 506186 MCHVY GLXYENT 0700 SJMHF SWRAF SCHYY WYNMY

3
Haeco jumps most on record in Hong Kong after Swire Pacific issues general offer

2018-06-11 scmp
Hong Kong Aircraft Engineering (Haeco) surged by the most on record on Monday after parent Swire Pacific proposed to take private the unit in a buyout valued at US$382 million because of illiquid stock trading.
SWRAY SWRBY 0700 SWRBF SWRAF

 
Swire Unit Haeco Surges as Parent Plans $382 Million Buyout - Bloomberg

2018-06-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SWRAY SWRBY CPCAY 0293 CPCAF SWRBF SWRAF 0044

 
HK stocks fall ahead of next week's Trump-Kim summit, Fed meeting

2018-06-08 theedgemarkets
SHANGHAI (June 8): Hong Kong stocks fell the most in two weeks on Friday, as investors braced for a series of market-moving events next week including the US-North Korea summit and the Federal Reserve's policy meeting.
SWRAY CRWOY SWRBY 0390 CGHLY CRWOF SWRBF SWRAF CGHOF 0384 1099

7
Cathay Pacific CEO vows to close gender gap as flight director’s departure means no women in Hong Kong airline’s top deck

2018-06-05 scmp
The number of female leaders in Hong Kong’s aviation sector has long trailed behind men but come this summer, the disparity will be made starker when Cathay Pacific Airways’ sole female leader, flight operations director Anna Thompson, leaves the city’s flagship carrier.
SWRAY SWRBY AIR 0293 ANZFY AIZ AC ACDVF ANZLY CPCAY ANZFF CPCAF SWRBF SWRAF

9
JetBlue's (JBLU) Traffic & Load Factor Increase in April

2018-05-11 zacks
JetBlue Airways Corporation (JBLU - Free Report) posted a rise in traffic figures for April. Traffic — measured in revenue passenger miles (RPMs) — improved 5.7% year over year to 4.3 billion. On a year-over-year basis, consolidated capacity (or available seat miles/ASMs) expanded 5.3% to 5.02 billion. Load factor or percentage of seats filled by passengers increased 40 basis points (bps) to 85.7% in the month as traffic growth outpaced capacity expansion.
SWRAY SWRBY SKYW CPCAY JBLU 0293 CPCAF LMHA SWRBF LMHB SWRAF LM

313
China Has the Cards to Call Trump's High-Stakes Trade Bet - Bloomberg

2018-04-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SWRAY CAT TM BOE AAPL GM INTC SWRBF PCRFY GEC GE SWRBY HYUO CATR TYT UTX TOYOF HYUD 7203 GNE HYUP LVS QCOM BA SWRAF

 
Investors in Li Ka-shing companies now face the big unknown of second generation leadership

2018-03-21 scmp
Conglomerates build by charismatic tycoons often don’t fare so well under second generation leadership who’ve been groomed for the role but lack street smarts
SWRAY SWRBY SWRBF SWRAF 0001

 
From factory worker to iconic billionaire: Li Ka-shing's success story

2018-03-16 channelnewsasia
HONG KONG: Li Ka-shing's rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world's biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

 
A factory worker at 13, Hong Kong's iconic billionaire Li Ka-shing retires

2018-03-16 reuters
HONG KONG (Reuters) - Li Ka-shing’s rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world’s biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

 
A factory worker at 13, Hong Kong's iconic billionaire retires - Channel NewsAsia

2018-03-16 channelnewsasia
Li Ka-shing's rise from penniless immigrant in 1940 to billionaire tycoon is the consummate success story in Hong Kong, a city which progressed alongside him from trading outpost to one of the world's biggest financial centers.
SWRAY HUWHF SWRBY CKHUF CKHUY SWRBF SWRAF 0001

 
Swire Pacific profit up by a half as property sales offset losses from aviation, marine services

2018-03-15 scmp
Underlying profit of HK$4.74 billion last year was still lower than the HK$5.27 billion forecast by analysts
SWRAY 1972 SWRBY SWROY CPCAY 0293 CPCAF SWPFF SWRBF SWRAF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 870794401